Literature DB >> 6352007

Serial immune function testing to predict clinical disease relapse in patients with solid tumors.

D P Braun, J E Harris.   

Abstract

Entities:  

Mesh：

Year:  1983        PMID： 6352007     DOI： 10.1007/bf00199159

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  51 in total

Review 1.  In vitro tests of cellular immunity in man.

Authors:  R B Herberman
Journal:  Invest Cell Pathol       Date:  1978 Jul-Sep

2.  Immunological tests in carcinoma of the prostate.

Authors:  C M Evans; J G Bowen
Journal:  Proc R Soc Med       Date:  1977-06

Review 3.  The biology and detection of immune complexes.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

4.  Immunologic reactivity in patients with primary operable breast cancer.

Authors:  H J Wanebo; H T Thaler; J A Hansen; P P Rosen; G F Robbins; J A Urban; H F Oettgen; R A Good
Journal:  Cancer       Date:  1978-01       Impact factor: 6.860

5.  Immunologic testing as a guide to cancer management.

Authors:  H J Wanebo
Journal:  Surg Clin North Am       Date:  1979-04       Impact factor: 2.741

6.  Failure of lymphocyte microcytotoxicity to distinguish relapsers from non-relapsers in melanoma patients receiving post-surgical adjuvant chemotherapy.

Authors:  J Berkelhammer; M J Mastrangelo; R E Bellet; R T Prehn; L H Thibault
Journal:  Eur J Cancer       Date:  1978-07       Impact factor: 9.162

7.  Persistent lymphocytopenia as a diagnostic feature of bronchogenic carcinoma.

Authors:  L J McMahon; S P Thomson; C A Nugent; W F Denny; T P Miller
Journal:  Chest       Date:  1980-10       Impact factor: 9.410

8.  Studies of the nonspecific cellular immune response in patients with urinary bladder carcinoma. I. PHA-induced lymphocyte transformation.

Authors:  S Nishio; A Horii; Y Morikawa; J Kawakita; T Nishijima; T Kishimoto; M Maekawa
Journal:  Invest Urol       Date:  1979-03

9.  Immunological monitoring and immunotherapy in carcinoma of the lung.

Authors:  J L Weese; R B Herberman; E Perlin; M Mills; W Heims; J Blom; D Green; J Reid; S Bellinger; I Law; J L McCoy; J H Dean; G B Cannon; J Djeu
Journal:  Int J Cancer       Date:  1976-12-15       Impact factor: 7.396

10.  Horizontal studies of cell mediated immune reactions to autologous tumour antigens in patients with operable mammary carcinoma.

Authors:  B M Jones; A R Turnbull
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640
View more
  4 in total

1.  Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.

Authors:  A P van der Meijden; P A Steerenberg; I M van Hoogstraaten; J A Kerckhaert; L M Schreinemachers; E J Harthoorn-Lasthuizen; A M Hagenaars; W H de Jong; F M Debruijne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy.

Authors:  W R Klein; P A Steerenberg; F Poelma; E vd Wiel; V P Rutten; W Misdorp; W H de Jong; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients.

Authors:  D D Taylor; D P Bender; J Stanson; T L Whiteside
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

4.  Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.

Authors:  L Molto; M Alvarez-Mon; J Carballido; L Manzano; C Guillen; A Prieto; C Olivier; M Rodriguez-Zapata
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.